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ALLERGIC rhin itis  is  a condition  w h ich  affe cts  ove r 15%
of the population  in  the United Kingdom . Th e patho-
logical process  in volves  tw o stages : nasal inflam m a-
tion , and the developm ent of nasal airw ay hyper -
responsiveness  (AHR) to allergen and a num ber of
other s tim uli. Th is  r esults  in  th e am plification  of any
subsequent allergic  r eaction , con tr ibuting to the
chron ic  allergic  s tate. A number of diffe ren t hypoth -
es es  have  been proposed to ex plain  th e underlyin g
m echan ism  of AHR, in cluding a role  for eosin oph il-
derived prote ins , fr e e radicals and neuropeptides .
Wh ile th ere m ay be a num ber of in dependen t path-
w ays wh ich can  re sult in  AHR, evidence  obtain ed
from  both  an im al m odels and in vivo ex perim ents  in
humans in dicate that som e m ediators  m ay in teract
w ith  one another, r esulting in  AHR. Fur ther re search
in to the se interactions m ay open new  avenues  for  the
pharm acological treatm ent of ch ronic  allergic  rh in i-
tis , and possibly other alle rgic airw ay diseases .
Key w ords: Human nasal airw ay, Hyperresponsiveness,
Eosinophils, Bradykinin, Neuropeptides, Nitric  ox ide
Introduction
Alle rgic  rhinitis and asthma are tw o of the most
common immunological disorde rs produc ing chronic
disease in man. For instance, alle rgic  rhinitis affec ts
over 15% of the  gene ral population.1 In both dise ases,
a local allergic  reaction results in an inf lammatory
response, causing w heezing and mucus sec retion in
asthma, and nasal congestion, rhinorrhoea (‘runny
nose ’), pruritis (itching) of the nose and sne ezing in
alle rgic  rhinitis. Continued ex posure to allergen
induces a state of chronic allergic  inflammation.
Contributing to this is the  deve lopment of airway
hyperresponsiveness (AHR), w hich re sults in the
amplification of any subsequent allergic  reaction.
While  a variety of pharmacological agents can be
used to treat the initial inflammatory response, only
steroids are effe ctive in preventing AHR. The mecha-
nism by w hich AHR occurs remains unclear. If the
mechanism of AHR can be  de scribed, then this may
provide  new  pharmacological targets  for the  treat-
ment of chronic allergic  airw ay disease. While allergic
rhinitis is not life-threatening, the same is not true for
chronic asthma, and the problem is  compounded by
the adve rse effe cts  associated w ith long-te rm steroid
use.
Unfortunate ly, animal models and in vitro ex peri-
ments are of limited value, s ince they are not
repre sentative  of the situation in man.2 ,3 How ever,
the human nasal airw ay is re asonably access ible  for in
v ivo rese arch into the  deve lopment of nasal AHR, and
may also yie ld some insight into the mechanism of
AHR in asthma. We re view  here  current hypotheses
for the  deve lopment of AHR in the  human nose, and
indicate potential new  pharmacologic al targe ts for
the tre atment of alle rgic  rhinitis and possibly other
alle rgic  airw ay dise ase s.
Pathogenesis of allergic rhinitis
There are tw o distinct forms of allergic  rhinitis,
depending on the allergen to w hich the subject is
sensitive. In perennial allergic  rhinitis (PAR), the
subject is ex posed to allergen throughout the  year,
w hile  in subjec ts w ith se asonal allergic  rhinitis  (SAR),
alle rgen ex posure is  limited to certain times during
the year. Subjec ts w ith PAR are  sensitive to alle rgens
including those  from the  house -dust mite (Derm a to -
pha go ide s  pte ro ny s s inu s ), other mites, animal dan-
ders and certain foods. In contrast, the  allergens
involved in SAR are  tre e and grass pollens , moulds and
ce rtain fungal spores .
Nasal inflammation
When particles of allergen are  inhaled into the nasal
cavity, they cross the nasal mucosa and are ex posed to
the immune  syste m; in susceptible  individuals, this
results  in sens itisation, a process w here  immunoglo-
bulin E (IgE) is synthe sised and becomes fix ed to
ce lls , such as mast ce lls. If the se cells subsequently
encounter the  same allergen, c rosslinking occurs
betw een IgE molecule s on the  cell surface , c ausing
the re lease of inflammatory mediators including
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histamine, kinins and eicosanoids, such as PGD2 ,
4 as
show n in Table 1. The se mediators  are  responsible for
the symptoms of alle rgic  rhinitis. Nasal blockage
results  from a combination of incre ased blood flow  to
the nose (causing swe lling of the  nasal tissue), plasma
ex travasation, and oedema. Rhinorrhoea is a con-
sequence  of the  stimulation of nasal sec retory glands,
w hich produce a mix ture of w atery or se rous
secretion and viscous mucus se cretion, mix ed
together w ith ex travasated plasma. Stimulation of
sensory nerves in the  nasal cavity causes  sneezing and
pruritis .
One method used to study the inflammatory
response in the  human nose is nasal lavage, w here  the
nasal cavity is rinsed w ith a solution (such as saline ),
and the  lavage  fluid subsequently colle cted and
analysed. Using this  technique , one  can measure  a
number of inflammatory mediators using appropriate
assays. Furthermore, by collecting and counting cells
present in the lavage fluid, it is possible  to correlate
the re lease  of inflammatory mediators w ith the
different cells observed.
The  response of subjects  w ith allergic  rhinitis  to
intranasal challenge  can often be divided into an
immediate phase, occurring during the first 2 h
follow ing ex posure to antigen, and, in about 30–40%
of subjects , a late  phase  occurring 6–12 h later. The
late phase is  associated w ith an infiltration of a
number of different inflammatory cells (including
eosinophils , neutrophils and T-lymphocyte s) to the
site  of inflammation, w here  they re lease a variety of
mediators including leukotriene s, c ationic  prote ins
such as eosinophil c ationic  prote in (ECP), and cyto-
kines (Table  1).
Intere stingly, the re  may be  difference s in the
prec ise  mediators involved in PAR and SAR. While
histamine is strongly associated w ith the  early phase
of SAR, histamine  H1 antagonists are not very e ffec tive
in reducing the early allergic  re sponse of PAR.
Instead, the kinins appear to be the  major mediator
causing symptoms in PAR.5 There is also evidence  that
the allergen (house dust mite ) in PAR can generate
kinin independent of the inflammatory response,
either by the dire ct ac tivation of kallikrein, the
enzyme w hich generates kinins,6 or by posse ssing
such biochemical activity itse lf.7
Nasal airway hyperresponsiveness
Nasal hyperresponsivene ss is  a hallmark of allergic
rhinitis .8 ,9 Subjects  w ith alle rgic  rhinitis show  an
incre ased response to nasal challenge  w ith a variety of
stimuli, including histamine and bradykinin, both of
w hich are re le ased follow ing allergen challenge. The
nasal airw ay e ffec tively becomes more sensitive to
alle rgen, contributing to the chronic alle rgic  state.
AHR is usually assoc iated w ith the late  phase reaction,
but can continue  w ell beyond this stage. In fac t, it is
induced irrespective  of w hethe r a late  phase  of
inflammation occurs.10
One important conside ration is the type of
response involved in AHR. In as thma, AHR is often
defined as an inc rease in the  contrac tile  response of
the airw ay smooth muscle. However, the re  is little
smooth muscle  present in the human nasal airw ay.
Nasal blockage results  from increased blood flow  to
the nasal mucosa, and not by an action on smooth
muscle. This highlights the difficulty of ex trapolating
data from the  nasal airw ay to the  low er airw ays, and
vice ve rsa. AHR is also assoc iated w ith increased
mucus production and oedema follow ing allergen
challenge, in both the upper and lower airw ays.
Therefore , AHR w ould appear to result from a dire ct
or indirect potentiation of the ove rall receptor
activation, and not simply from an ac tion on a
particular ce ll type alone . With this in mind, there  are
a number of pote ntial mechanisms by w hich AHR
might occur (Fig. 1).
(1)  The  in fla m m a to ry  ca s cade :
Initial ex posure  to alle rgen might trigge r a cascade
reaction, causing inc reased mediator re le ase and,
therefore , greate r receptor activation. For instance,
subjects w ith SAR ex perience  inc re as ingly severe
symptoms as the  pollen se ason continue s. How ever, a
number of inflammatory mediators can induce AHR in
the absence of any othe r mediator. Furthermore, the
development of AHR can occur independently of a
chronic inflammatory re sponse .10 It is likely, there-
fore , that the  AHR potentiate s the effe ct of the
inflammatory cascade  se en in chronic  alle rgic  rhinitis,
rathe r than being caused by it.
(2)  Increa s ed expo s u re  o f re cepto r s  o n  th e  na s a l
m u co s a  to  the  s tim u lu s :
A common histologic al finding in chronic  airw ay
alle rgy is  the damage and shedding of epithelial c ells
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Table 1. Mediators found in nasal lavage fluid collected
following both the immediate and late phase response in
atopic individuals challenged intranasally with allergen4
Mediator Immediate
phase
Late
phase
Histamine 33 33
TAME-esterase 33 33
Prostaglandin D2 33 7
Leukotrienes LTB4 /C4 /D4 3 3
Kinins 33 3
Platelet-activating factor (PAF) 3 7
Albumin 33 33
Neuropeptides, e.g. CGRP and VIP 3 7
Substance P 3 3
Eosinophil-derived mediators,
e.g. ECP, MBP
7 33
Interleukin 1 (IL-1) 3 3
IL-3, IL-4, IL-5, IL-6, TNFa 7 3
lining the airw ay. The airw ay epithe lium can act as  a
physical barrier betw een the  airw ay lumen and the
underlying mucosa. There fore, removal of these  cells
w ould increase  the  ex posure of the  receptors on the
mucosa to any stimulus present. For ex ample , in the
low er airw ays, removal of the airway epithe lium
incre ases the response of smooth muscle in both
animal models and human bronchi ex  vivo .11 While
there  may be a link betw een epithe lial shedding and
the presence of AHR in alle rgic  individuals ,12 media-
tors w hich induce AHR on the ir ow n (e .g. plate let-
activating factor) do not cause  epithelial shedding in
the time taken for AHR to deve lop, though the doses
required are tox ic  to airw ay epithe lial c ells.13 Alterna-
tively, the loss  of airw ay epithe lial c ell func tion, but
not ne ce ssarily barrier func tion, may be sufficie nt to
induce AHR.1 4 In the human nasal airw ay, AHR to
bradykinin is unlikely to be  due to a reduction in
epithe lial barrie r function,15 and the re  is no evidence
for increased epithe lial permeability in subjec ts w ith
alle rgic  rhinitis.1 6 Mediators such as PAF may also
damage  the  mucoc iliary clearance system linked to
the airw ay epithe lium, contributing to the AHR.13
(3)  Mo du la tin g  a gen ts :
The ability of ace tylcholine  to cause vasodilatation in
the vascular system is dependent upon the re lease of
nitric  ox ide from the endothe lium (and possibly other
mediators, colle ctive ly know n as endothe lium-
derived re lax ing fac tors). It has been proposed that
airw ay epithelial c ells may gene rate mediators, such
as arachidonic ac id metabolites , nitric  ox ide and the
putative epithelium-de rived re lax ing fac tor (EpDRF)
(also know n as EDHF (epithelium-de rived hyper-
polarsing fac tor)) w hich modulate the re sponsivene ss
of the airw ays. How ever, the evidence  for such
mediator re lease from airw ay epithelial c ells is equiv-
ocal.1 1,17 –1 9 The epithe lium may have  an important
role  in the metabolism of various stimuli, particularly
adenosine ,2 0 tachykinins1 8 and ace tylcholine .21 Loss
of epithe lial ce ll function might reduce  the  metabo-
lism of the se mediators, enhancing their ability to
activate receptors and e ffec t a response. How ever,
epithe lial damage can occur w ithout the  presence  of
AHR, and vice ve rsa.22 For ex ample , cationic prote ins
can cause AHR w ithout any apparent damage to the
epithe lium.2 3
(4) Re cepto rs :
AHR may result from a change  in the characteristic s of
receptors located on the  nasal mucosa. For ex ample,
cholinergic  agonists such as methacholine cause  more
secretion in alle rgic  subjects than in non-allergic
controls, and this  could be ex plained by an inc rease
in the density of choline rgic  receptors .24 How ever,
the density of muscarinic  re ceptors on nasal tissue
from allergic  subjects may actually decrease  slightly,
possibly as a result of adaptation due to over-
stimulation, although the  remaining receptors ex hibit
an inc re ased affinity, w hich might contribute  to the
hypersecretion.25 No significant difference s have
been found for a - or b -adrenoceptors .26 The minor
changes observed are probably a re sult, rather than
the cause, of AHR.
(5)  Me tabo lis m :
Alternatively, AHR may be a consequence of prolonged
activity of a varie ty of mediators, due to an e ffec t on
their metabolism. For ex ample, neuropeptide s are
degraded by neutral endopeptidase  (NEP), and the
activity of NEP is significantly lower in subjects  w ith
nasal AHR.27 A second protein, lac tofe rrin, may
prevent antigen-induced AHR in the low er airw ays of
sheep by inhibiting tryptase.2 8 Though the  pre cise  role
of tryptase  in airw ay alle rgy is not fully know n, it c an
induce AHR in the lower airw ays of sheep29 and in e x
v ivo tissue from human bronchi.3 0
(6)  Alte red in tra ce llu la r s igna llin g :
Finally, the intracellular pathw ays w hich are activated
by the  receptor/agonist complex  may be  altered in
AHR. Of particular interest is  phosphodiesterase  IV
(PDE4), an enzyme w hich catalyses  the  metabolism of
a number of intrace llular messenge rs, such as cyclic
GMP (cGMP). While  PDE4 inhibitors abolish AHR in
animal mode ls,31 the  data in human asthmatic sub-
jects are equivocal,3 2 and the re  are no data w ith
respect to the  human nasal airw ay. Inte re stingly,
inhibitors  of nitric ox ide  synthase  can also cause AHR,
possibly by reducing the amount of cGMP.33 AHR
could re sult from a loss of a compensatory mecha-
nism, involving cGMP; such a mechanism may be fre e
radical dependent.34 In the  chronic  allergic  state , AHR
Nas a l a irw ay  hype rre s po n s iven e s s
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FIG. 1. Potential mechanisms in the development of AHR.
¶ Inflammatory Cascade; · altered exposure of the receptor
to the stimulus; ¸ release of modulating agent by other cells;
¹ change in the receptor properties; º altered metabolism of
the mediator; » altered regulation of the intracellular signal-
ling resulting in the response.
may result, in part, from a change in gene  transcrip-
tion w ithin cells (e.g. the  NF-kB transc ription system),
though the timescale  of onset of hyperre sponsivene ss
make s this  process  unlike ly in the  induction of AHR.
Mediators implicated in the development
of AHR
In 1933, Sir Henry Dale  described a number of crite ria
w hich should be used to identify potential inflamma-
tory mediators. Applying the se to the  development of
AHR:
d administration of the potential mediator should
cause AHR in vitro and in  vivo ;
d the  mediator should be present in appropriate
concentrations in alle rgic  individuals w ith AHR;
d the  mechanisms involved in the gene ration of the
mediator should be  present and incre ased in
AHR;
d a mechanism should ex ist to terminate the action
of the  mediator (important, because  AHR is a
reversible  phenomenon);
d antagonists  of the mediator reduce  the  induction of
AHR;
d re ceptors/s ignalling pathw ays should be present in
the nasal mucosa, and be ac tivated by the
mediator.
The process by w hich AHR occurs re mains unclear,
no doubt due, in part, to the  complex ity of the
mechanism and the  difficulty in regulating the proc-
ess under controlled ex pe rimental conditions. None-
theless, because  it is assoc iated w ith the  influx  of
ce lls  to the site  of inflammation, a number of
hypotheses have  been proposed involving mediators
re leased from the se cells. One  particular c ell type, the
eosinophil, has been implicated in AHR. In both SAR
and PAR, antigen challenge  re sults in an inc rease of
eosinophils  in the  nasal mucosa and the re lease  of
various eosinophil-derived mediators .35 – 39 Conse-
quently a major role has  been proposed for eosino-
phils  and the ir proteins in this process.
Eosinophil granule-derived proteins
Eosinophils contain granule s composed of four basic
prote ins. The core  of these granule s is  major basic
prote in (MBP), w hile  the matrix  surrounding the  core
is composed of eosinophil c ationic  protein (ECP),
eosinophil-derived neurotox in (EDN) and eosinophil
perox idase (EPO).40 The possible  role s of these
prote ins in allergic  airw ay disease  are described in
Table  2.
The  levels of ECP, EPO and MBP are  raised
follow ing antigen challenge in alle rgic  rhinitis ,37 – 3 9,4 1
and these inc re ases often coincide w ith the presence
of AHR. MBP and othe r cationic  prote ins, including
the synthetic protein poly-L-lysine, cause AHR in the
low er airw ays of rats ,23 w hich appears to be  depend-
ent on the ir cationic charge. How ever, no study has
ye t been conducte d to investigate w hether the se
cationic proteins can themselves  induce AHR in the
human nasal airw ay.
The  mechanism of MBP-induced AHR is unknow n,
though it may be  dependent on causing epithelial
damage , s ince  MBP only induce s AHR in guinea pig
tracheal preparations w ith an intac t ep ithe lium.4 2
However, as stated above , cationic  prote ins may
induce AHR w ithout causing epithe lial damage.2 3
Furthe rmore , although all the eosinophilic cationic
prote ins are cytotox ic  to the  airw ay epithe lium,4 3
only MBP caused AHR in a study on primate s.4 4 In the
low er airw ay of the rat, AHR induced by MBP or poly-
L-lys ine is abolished by both neurokinin NK-14 5 and
bradykinin B24 6 antagonists , indicating a role for
substance P and the kinins in the development of
AHR. It is also possible  that eosinophil cationic
prote ins act on othe r inflammatory cells to generate
the conditions required for AHR.2 2 While  there  is
evidence  for a re lationship betw een ECP levels in
nasal lavage and nasal AHR,47 this has  not alw ays be en
reproduced in other studie s,48 ,4 9 so ECP is unlikely to
be solely responsible  for the  induction of nasal AHR.
Platelet activating factor (PAF)
PAF is a naturally occurring phospholipid, and is the
only endogenous compound know n to induce AHR in
both animals and man.50 In normal, non-atopic
subjects, it induce s a nasal AHR to histamine  and
bradykinin5 1,5 2 and causes  an inc re ased re sponse  to
pollen in subjec ts w ith SAR.51 The  re sulting AHR is
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Table 2. Cationic proteins found in eosinophil granules40
Protein Cell content
( m g/106 cells)
Role in allergic airway disease
MBP 9 d causes histamine release from
basophils and mast cells
d cytotoxic for human epithelial
cells
d causes bronchoconstriction and
induces hyperresponsiveness in
animals
d activates neutrophils
ECP 5 d causes histamine release from
mast cells
d cytotoxic to a variety of cells
EDN 3 d undefined
EPO 12 d cytotoxic to airway epithelium
d provokes bronchoconstriction
in animals
d in the presence of H2O2 and
halide, causes mast cell
degranulation and histamine
release and inactivates
leukotrienes
similar, in many w ays, to that observed in allergic
rhinitis, as  PAF also cause s a s ignificant nasal neu-
trophilia and eosinophilia, toge the r w ith raised ECP
levels in nasal lavage  fluid.52 – 54
Although PAF can induce AHR in the  human nasal
airw ay, its  role in allergen-induced AHR is  less de fined.
Antigen challenge w ith grass  pollen in atopic  individ-
uals w ith SAR causes  the re lease  of lyso-PAF and
PAF,41 ,55 but it is  unclear w hether PAF or lyso-PAF are
re leased in PAR,56 One possibility is  that any PAF
generated is  conve rted to lyso-PAF by acetylhydrolase
present in the lavage fluid. The ac tivity of this  enzyme
in lavage  fluid is significantly raised follow ing grass
pollen challenge in sens itive subjects.41 ,57
PAF may ac t direc tly on the nasal mucosa, and
radioligand binding studies  indicate the pre sence of
specific binding site s for PAF in human lung tissue,5 8
but no such studies have  yet been performed using
tissue obtained from the  human nose . One of the
main fe atures  of PAF is its ability to attract and ac tivate
a variety of inflammatory cells, including eosinophils,
neutrophils , monocyte s, macrophage and platele ts.5 0
PAF may also re lease  from airw ay epithe lial c ells a
range  of chemotactic  fac tors for neutrophils and
eosinophils , including the  cytokine GM-CSF.5 9 The
subsequent ac tivation of these ce lls w ill re le ase a
range  of mediators  w hich can act on othe r ce lls  in the
airw ay. Administration of PAF into the  nasal airw ay
also causes  ECP re lease, w hich could then contribute
to the  AHR.5 2,53
If PAF is an important mediator of nasal AHR, one
w ould ex pect PAF-antagonists to reduce leukocyte
infiltration and inhibit antigen-induced AHR. While
this e ffec t has  been obse rved in some studie s using
animal models,6 0 – 6 2 the  PAF antagonists  WEB 20864 1
and UK 74,50563 did not alter AHR in the  human nasal
airw ay. How eve r, both these  antagonists ex hibit a low
potency for PAF re ceptors, and may cause  only a w eak
inhibitory ac tion in man.
PAF causes mucosal dysfunction and damage,
inhibiting ciliary action and inc re as ing ex foliation of
the epithelial lining of the  airw ay both in vivo in the
low er airw ays of the  rabbit13 and in v itro using
ex plants from human nasal mucosa.6 4 Intere stingly,
the latter study found that PAF is  itse lf cytotox ic  to
epithe lial c ells, w ithout requiring the production of
othe r cytotox ic  mediators. PAF-induced AHR in the
human nasal airw ay w as almost abolished by pre treat-
ment w ith the  antiox idant vitamin E,52 implying a
mechanism w hich is dependent on the  gene ration of
free radicals. This supports  the  hypothesis  that PAF
causes  tissue damage  w hich may be independent of
the re lease  of other mediators, perhaps via the
generation of fre e radicals. The  source of the  fre e
radicals could be  the epithe lial ce lls , so in effec t, the
epithe lium may cause its ow n destruc tion.65
It is  unclear, how eve r, w hether sufficie nt quantities
of PAF are produced in the antigen-induced allergic
response to cause AHR, and there  are  probably
differences in the  underlying mechanism of AHR
induced by PAF and antigen.
Leukotrienes
The leukotrienes are generated by the action of
5-lipox ygenase  on arachidonic ac id. They are  re leased
in both the  early and late  phase s follow ing antigen
challenge in subjec ts w ith SAR66 and during the early
phase  in PAR.67 There are tw o classes of leukotriene s:
LTB4 and the peptidyl-cyste inyl leukotrienes (LTC4 ,
LTD4 and LTE4 ). The  latte r group are  synthe sised by
eosinophils  (among other cells) and cause a long-
lasting eosinophilic  infiltration, and have been asso-
ciated w ith AHR in the low er airw ays in rats6 8 and in
man;69 both these ac tions appear to be dependent on
eosinophil activation. Although inhibitors of leuko-
triene synthesis  reduce  the  nasal blockage ex peri-
enced follow ing challenge  w ith grass  pollen in
alle rgic  subjec ts,7 0,7 1 no studies have investigated the
effect of such drugs on AHR in the  human nasal
airw ay, though zileuton, a lipox ygenase inhibitor,
reduced antigen-induced AHR in the  lower airw ays of
asthmatics.7 2 Pharmacologic al intervention can also
be achieved at the leve l of the receptor, and a number
of leukotriene  receptor antagonists have  be en devel-
oped w hich inhibit AHR in animal models.73 Many of
these  are currently under study in man, including
pranlukast, w hich may reduce  AHR in as thmatic s,7 4
and monte lukast, w hich has recently been approved
for use in the  USA. The role  of LTB4 in AHR is  not cle ar,
but LTB4 antagonists have be en show n to inhibit
antigen-induced AHR in the  lower airw ays of pri-
mates75 and the  guinea pig.76 Although human
eosinophils  cannot produce  LTB4 because  they lack
the enzyme  ne eded for its  synthe sis, it is the  main
lipox ygenase  product in neutrophils, and acts as  a
potent stimulus for leukocyte  infiltration and sub-
sequent degranulation.77
Prostaglandins and thromboxanes
The prostaglandins PGD2 and PGE2 are de tec ted at
inc re ased leve ls  in nasal lavage fluid follow ing aller-
gen challenge in subjects w ith SAR7 8,79 and PAR,80 but
only in the e arly response and not the late  phase  of
inflammation.6 6 Inhibitors of cycloox ygenase, the
enzyme required for the synthe sis of prostaglandins,
do not affe ct the re sponse  to antigen in the  human
nasal airw ay.6 6 PGE2 is synthe sised by the airw ay
epithe lium and has been proposed as  a poss ible
EpDRF. In the lower airw ays, AHR may re sult from
epithe lial damage, reduc ing PGE2 gene ration by
epithe lial c ells and, therefore , decreasing its  re lax ant
effect on airw ay smooth muscle .81 How ever, in the
human nose , any action of PGE2 would presumably
have to be  on blood ve sse ls  (since there  is little  airw ay
Nas a l a irw ay  hype rre s po n s iven e s s
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smooth muscle in the  human nose ), and one w ould
also ex pect a dec rease in PGE2 re lease if it w as
involved in AHR, yet the opposite  is  true. Thrombox -
ane  A2 (TxA2 ) doe s appear to mediate  AHR in animal
mode ls82 ,8 3 and may do likew ise in man.84 Inhibition
of thrombox ane synthesis  reduce s AHR and also
inhibits airw ay eosinophilia afte r alle rgen challenge.8 5
The thrombox anes may, the refore , have an important
role  in upregulating the eosinophil-associated
response.7 7 The contribution of thrombox ane s to
nasal allergy re mains undefined, and more research is
ne eded to investigate  their potential role in the
development of AHR.
Neuropeptides
Sensory ne rve fibres contain a number of different
peptide s, including calcitonin gene-re lated peptide
(CGRP) and the tachykinins substance  P (sub P) and
neurokinin A (NK-A). These  neuropeptides, metabo-
lised inte r  a lia by the enzyme  neutral endopeptidase
(NEP), are re leased from sensory nerves w hich form
part of the non-adrene rgic  non-cholinergic  (NANC)
ne rvous system, and are  capable  of gene rating a local
ax on reflex  w hich causes an inc rease in vascular
permeability, plasma leakage  and subsequent tissue
oedema. This response is  know n as neurogenic
inflammation, and is mediated by the  tachykinin NK-1
and NK-2 re ceptors. In addition, eosinophils are
capable  of producing vasoac tive  inte stinal peptide
(VIP) and sub P.8 6 All these  neuropeptides are found in
nasal sec re tions follow ing nasal challenge  w ith grass
pollen,87 but the ir role in AHR remains unclear.
However, the re  is a correlation be tw een the presence
of AHR and the ac tivity of NEP in the human nose.2 7
Furthe rmore , in both PAR and SAR, AHR to bradykinin
is mediated by neural re flex es,1 5 w hich could con-
ce ivably include  a role  for neuropeptide s.
Neuropeptide s appear to be important in AHR in
a variety of animal mode ls . In the  low er airw ay of
the rat, AHR induced by eosinophil-derived cationic
prote ins is  inhibited by neurokinin NK-1 receptor
antagonists and capsaic in.45 In the guinea pig, appli-
cation of capsaicin to the  low er airw ay (an action
w hich deple tes  sensory nerve s of neuropeptides)
also abolishes antigen-induced AHR.88 ,8 9 The tachyki-
nins, particularly sub P, may enhance eosinophil
rec ruitment90 ,91 and, there fore , cause AHR via an
eosinophil-dependent mechanism. However, the
inhibition of AHR by capsaic in does not affec t
lipox ygenase  activity or eosinophil infiltration, sug-
gesting that neuropeptides cause AHR independently
of, or afte r, eosinophil activation and leukotriene
synthesis.89
Neurogenic  inflammation may be  a phenomenon
only found in animals, s ince  one study found no
evidence  of capsaic in-induced neurogenic inflamma-
tion in the human nasal airw ay.92 However, other
studies , some utilising higher doses of capsaicin,
confirm that neurogenic  inflammation does occur in
alle rgic  rhinitis.93 ,9 4 Furthermore, application of cap-
saicin re duces the  symptoms caused by antigen
challenge in SAR95 and PAR96 , though ne ithe r of
these  studie s investigated AHR. It is , there fore , possi-
ble  that AHR in the  human nasal airw ay may result,
at least in part, from an upregulation of neurogenic
inflammation, possibly due to epithelial damage
incre as ing the  ex posure of sensory nerves. Bradyki-
nin causes neuropeptide re lease in vivo in the
human nasal mucosa,97 w hile histamine  has a s imilar
effect on human lung tissue e x  vivo .98 Damage to
the airway epithelium may inc rease ex posure of
sensory ne rves to stimuli, e ffec tively causing an
upregulation of neurogenic inflammation. This
w ould result in increased neuropeptide re lease,
w hich might further pote ntiate AHR, perhaps by
dire ct e ffec ts on inflammatory ce lls (e.g. eosino-
phils) or by stimulating cytokine re lease from cells
in the  nasal mucosa, a proce ss w hich occurs  in the
human nasal airw ay.99
Alte rnative ly, neuropeptides may not just upregu-
late the inflammation re sulting in AHR, but also
dire ctly cause  the inc re ased re sponse observed in
AHR. A number of stimuli, including antigen, cause
neuropeptide  re lease  in the  human nasal airw ay. If
tachykinin ac tivity is potentiated, due to more neu-
ropeptide re lease or inhibition of metabolism, this
w ould cause an inc rease in neuropeptide-mediated
symptoms such as nasal obstruction and rhinor-
rhoea: in effect the  ‘hype r’-response observed in
AHR. Phosphoramidon, a NEP inhibitor, c an cause
AHR in the  low er airw ays of guinea pigs1 00 and
man,10 1 and potentiate s the ac tivity of neuropep-
tides in the  human nasal airw ay.10 2 NEP is  pre sent in
the human nasal mucosa,1 03 and correlates w ith the
presence of nasal AHR.2 7 Epithe lial damage  may
cause AHR by reducing the  activity of NEP asso-
ciated w ith airw ay epithelial cells. Howeve r, in the
human nasal airw ay, PAF-induced AHR is not asso-
ciated w ith the re lease  of sub P (Fig. 2). PAF may
cause AHR by a different mechanism to antigen, the
former being independent of neuropeptide  re lease.
Alternatively, PAF may potentiate subsequent neu-
ropeptide re lease from sensory nerve s, and not
cause neuropeptide re lease pe r s e , so an inc re ase in
sub P w ould only occur in the presence  of a further
stimulus, such as histamine .
It is unknow n w hich particular neuropeptides may
be involved in the  deve lopment of AHR. Sub P is the
most pote nt endogenous mediator at the NK-1
receptor, but it doe s not induce AHR in the  low er
airw ays of sheep, w hile  NK-A doe s.10 4 In the human
nasal airway, NK-1 receptors  are  localised to the
epithe lium, glands and blood ve ssels , w hile  NK-2
receptors are limited to arterial vessels .105 This is in
agreement w ith the  findings that nasal obstruc tion is
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mediated through the  NK-1 receptor, w hile  plasma
ex travasation probably involve s both NK-1 and NK-2
receptor activation,1 06 and would ex plain the  incon-
sis tency that NK-1 or NK-2 re ceptor antagonists
prevent AHR in some studie s but not in others . In
chronic asthma, both receptor subtypes are upregu-
lated,10 7 and this may happen in chronic allergic
rhinitis as w ell. There  are  no re ports investigating the
role  of CGRP in AHR.
Cytokines
Cytokine s are  inte rc ellular messenger peptides w hich
are  re leased by a variety of c ells to influence  the
activity of othe r ce lls. Three  cytokines are of vital
importance  in the  development and regulation of
eosinophil func tion: the interleukins IL-3 and IL-5, and
granulocyte-macrophage  colony-stimulating factor
(GM-CSF). All thre e pre vent apoptosis  and prolong the
survival of eosinophils  in vitro , and in particular, IL-5
is essential for the diffe rentiation of progenitor cells
into eosinophils.1 08
Both IL-4 and IL-5 have been implicated in the
development of AHR.10 9 In animals, IL-5 cause s a
marked eosinophilia, eosinophil ac tivation and AHR.9 1
Monoclonal antibodies to IL-5 abolish antigen-induced
eosinophilia and AHR in the low er airw ay of the
guinea p ig.1 10 IL-4 regulate s the  ac tivity of CD4+
T-lymphocyte s, w hich re lease a range  of cytokine s
capable  of priming and activating eosinophils,71 and
can also ac tivate neutrophils.1 11 Furthe rmore , mem-
ory T-ce lls in the  nasal mucosa of patients w ith nasal
alle rgy can produce IL-4 during allergen ex posure,
w hich may upre gulate  the  inflammatory response .11 2
Patients w ith SAR or PAR have a raised number of
CD4+  T-cells.11 3
Follow ing nasal allergen challenge, the levels of IL-
1 a , IL-1 b , IL-5, IL-6, IL-8 and GM-CSF are raised in
nasal sec re tions,1 14 –11 6 and human eosinophils are
potential source s of these  cytokines.1 17 Epithelial
ce lls , isolated from allergic  rhinitics , showed
incre ased immunostaining for GM-CSF, IL-8, the recep-
tors for IL-1 and TNF-a ,11 8 and also they re lease more
IL-1 b , IL-8, GM-CSF and TNF-a compared to epithelial
ce lls  from non-alle rgic  subjects.1 19 Similar inc reases in
IL-4-, IL-5- and GM-CSF-positive cells are  observed in
biopsie s  from the  nasal mucosa of atopics .12 0 Both
inte rferon-g and TNF-a (and possibly other cytokines)
cause an upre gulation of ICAM-1 on human nasal
epithe lial cells,1 21 w hile  IL-4 upregulates the ex pres-
sion of VCAM-1.11 3 Both these adhesion molecule are
upregulated in alle rgic  rhinitis .113
Cytokines may promote  AHR by upregulating the
rec ruitment and activation of eosinophils (Fig. 3)
and neutrophils . For ex ample , there  are close  corre-
lations betw een the  number of eosinophils and GM-
CSF leve ls in bronchoalveolar fluid (BALF) from
subjects w ith asthma,1 22 w hile the survival of eosi-
nophils in BALF from subjects  w ith alle rgic  rhinitis
correlates  the concentrations of IL-5 and GM-CSF
present.1 23 Neurokinin NK-2 re ceptor antagonists
inhibit AHR induced by IL-5 in the guinea pig, but
not the associated eosinophilia,1 24 indicating that
cytokines are involved in ce ll rec ruitment, follow ing
w hich various mediators are  re le ased, such as neu-
ropeptides w hich may cause the development of
AHR. IL-1 may also be  involved in the  deve lopment
of AHR,12 5 but it has a w ide  range of c ellular ac tions,
so it is difficult to suggest a pre cise  role for it in the
pathogenesis of AHR. Intere stingly, it may inhibit the
activity of NEP,12 6 or induce  the  gene ration of
ox ygen-based fre e radicals from macrophages and
neutrophils .12 7
Finally, glucocorticoids dow nregulate the  produc-
tion of IL-3 and IL-5 follow ing alle rgen challenge; this
effect may contribute to the  action of steroids in
abolishing AHR,11 6 although glucocorticoids have
othe r ac tions too.
Nas a l a irw ay  hype rre s po n s iven e s s
Mediators of Inflammation ´ Vol 8 ´ 1999 139
FIG. 2. The effect of PAF on the concentration of substance P
in nasal lavage fluid. The nasal airway was challenged with
either saline or PAF, 60 m g, and the airway was lavaged 2, 4
and 6h after challenge. Following lavage, a peptidase
inhibitor was added to prevent degradation of substance P
prior to assay. Data are means± SEM from nine subjects.
FIG. 3. Role of cytokines in the modulation of eosinophil
function in allergy.71
Chemokines
Chemokines are cytokine s w hich posse ss chemotac tic
activity, and are  divided into groups depending on
their structure. The  tw o main groups are  CC chem-
okine s, w here  tw o cyste ine  re sidue s are  adjacent to
each other (e.g. RANTES, MIP-1 a , eotax in) and CXC
chemokines, in w hich the tw o cyste ine re sidue s are
separated by a third amino acid (e.g. IL-8). Some
chemokines (RANTES, eotax in) appear to be se lec tive
for eosinophils, w hile  IL-8 has  a chemotactic  ac tivity
only for neutrophils  (though there  are re ports that it
also has  an action on primed human eosinophils).1 28
The  levels of RANTES,1 15 ,1 29 MIP-1 a ,1 15 eotax in13 0
and IL-811 5,13 1 dete cted in nasal lavage  are  raised
follow ing nasal allergen challenge in man. Treatment
w ith glucocorticoids, w hich inhibits inflammatory
ce ll re cruitment, abrogate s these  incre ase s.1 15 ,13 2
Interestingly, mucosal c ells obtained from the  nose s
of subjects  w ith allergic  rhinitis show  increased
ex pre ssion of mRNA for RANTES1 29 and eotax in.1 30 It
is now  generally accepted that RANTES and eotax in
are  important in IL-5-mediated eosinophilia, w here
the latte r cause s the  mobilisation of eosinophils into
the circulation w hile  the  local re lease of chemokines
provide s a ‘homing’ mechansim for the migration of
eosinophils  into the  tissues.12 8 How ever, no study has
ye t investigated the spec ific  role s of chemokine s in
nasal hyperre sponsivene ss. Notw ithstanding, admin-
istration of RANTES into the nasal airw ay of subjec ts
w ith alle rgic  rhinitis  causes an eosinophilia but not an
influx  of other inflammatory cells.1 33 How ever, the
same study also found that, after allergen challenge,
administration of RANTES also caused an influx  of
basophils, neutrophils, lymphocytes and monocytes,
as w ell as causing epithelial shedding, a response
similar to that obse rved in nasal hyperre sponsivene ss.
It is there fore  likely that chemokines have  an impor-
tant role in the  recruitment of inflammatory cells that
is obse rved during the deve lopment of nasal
hyperresponsiveness.
Nitric oxide
Recently, a large  amount of rese arch has been carried
out on the  role  of nitric  ox ide  in airway disease . There
is e vidence that nitric ox ide synthase  (NOS) activity is
inc re ased in PAR134 and in SAR.13 5,13 6 This would
incre ase the amount of nitric  ox ide  available  to react
w ith supe rox ide , gene rating free  radicals w hich may
contribute  to the deve lopment of AHR.33 Nitric ox ide
may also have  a role in the production of cytokine s
ne cessary for eosinophil survival, such as IL-4 and IL-
5.13 7 Therefore , one  might ex pect inhibitors of NOS
to prevent AHR, either by re duc ing free radical
production or via the  induction of eosinophil apopto-
sis . Paradox ically, NOS inhibitors  actually induce AHR
to histamine and bradykinin in both the human nasal
airw ay1 38 (Fig. 4) and low er airw ays of asthmatic s,13 9
and also in animal mode ls.14 0 It is possible  that in the
normal, non-inflamed airw ay, nitric ox ide  is pro-
te ctive, so inhibitors  of NOS w ould cause  AHR, but in
chronic airw ay inflammation, an inappropriate
degree of nitric ox ide production may be harmful and
potentiate the allergic  response.
Intere stingly, NO is thought to be the  central
mediator of inhibitory NANC transmission. There fore ,
inhibition of NOS may cause a reduction in the
activity of inhibitory NANC ne rves, w hich could
cause AHR by potentiating neurogenic inflammation
mediated by ex citatory NANC ne rves. In chronic
alle rgy, ex cessive NO production could cause  AHR by
the formation of the perox ynitrite  fre e radical, w hich
causes  AHR in the guinea p ig airw ay, poss ibly by
inhibiting cGMP production.33 Furthermore, other
NO metabolite s, such as nitryl chloride, can be
synthesised by neutrophils, inactivating endothelial
ce ll angiotensin-converting enzyme .141 This enzyme is
involved in the degradation of kinins and possibly
tachykinins in allergic  rhinitis ,10 2,1 42 so inhibition of
this enzyme  may influence  AHR by potentiating the
action of these  mediators .
Kinins
A number of studie s have  identified a role  for kinins in
the deve lopment of AHR in the  low er airw ays of both
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FIG. 4. The percentage decrease in the minimal cross-
sectional area of the nasal airway (Am in ) from baseline
10min after challenge with histamine, 200 m g. The nasal
cavity was pretreated every 30min with saline, a NOS
inhibitor (L-NAME or L-NMMA, 1 m mol), or L-NAME together
with L-arginine, 30 m mol, for 6h prior to the histamine
challenge. Data are means± SEM from 10 subjects. **,*Sig-
nificant increase in the histamine-induced percentage
change in Am in following pretreatment with a NOS inhibitor
compared to saline pretreatment (*,**P<0.05 and P<0.01,
respectively, Wilcoxon sign-rank test).
the guinea pig14 3 and sheep.1 44 Furthermore, the
ability of MBP and synthe tic cationic  prote ins to
induce AHR in the  low er airw ays of rats  is dependent
on the  gene ration of kinins.4 6 In all three  studies,
administration of a bradykinin B2 re ceptor antagonist
inhibited the deve lopment of AHR, and, w here
investigated, also appeared to have  an effect on the
rec ruitment of eosinophils  into the airw ay. ECP can
stimulate kallikre in activity in v itro ,14 5 re sulting in
kinin production, so eosinophil-de rived cationic pro-
te ins may generate  kinins w hich lead to AHR.
Recent investigations have  found that AHR in the
human nasal airw ay may also be  kinin dependent.
Ic atibant, a highly potent antagonist at the bradykinin
B2 receptor, prevents PAF-induced AHR (Fig. 5), w hile
PAF cause s an incre ase in the level of kinins in nasal
lavage fluid (Fig. 6). Kinins are produced in both PAR
and SAR, and could therefore  contribute  to AHR in
alle rgic  rhinitis.
One important conside ration is the source  of the
kinins. In SAR, antigen challenge causes  an inc re ase in
plasma ex travasation, so the kinins dete cte d may be a
product of plasma kallikre in activity. How ever, antigen
doe s not induce plasma ex travasec tion in PAR,5 and
the role of plasma kallikrein has not been assessed in
either alle rgic  rhinitis  or as thma.1 46 The  leve ls  of tissue
kallikrein in nasal sec retions are inc re ased in allergic
rhinitis ,1 47 but it is not thought that tissue  kallikrein
can be  activated by cationic prote ins.4 6 A novel
solution to this anomaly is as follow s. Neutrophils
contain tissue kallikre in and bind plasma kallikrein,
together w ith high- and low -molecular we ight kinino-
gen, on the ce ll surface.1 48 ,14 9 Antigen and PAF
challenge cause  a neutrophilia in addition to eosino-
phil re cruitment,54 therefore  neutrophils  may provide
the components needed for the  gene ration of kinins.
The  mechanism by w hich kinins induce  AHR
remains unknow n. Ex ogenous kinins applied to the
airw ays do not cause  AHR in animal models4 6 nor in
the human nasal airw ays (Turner & Foreman, unpub-
lished data), though one  study found that bradykinin
can produce  AHR to ace tylcholine  in the guinea pig
airw ay.1 50 Bradykinin causes sensitisation of C-fibres
in the guinea pig trachea,1 51 and the re  is e vidence
that in the  human nose enhanced responsiveness to
bradykinin is mediated by neural re flex e s.15 Bradyki-
nin can also re lease sub P and other neuropeptides
from sensory nerve endings,98,15 2 so it may induce
AHR by a neuropeptide -dependent mechanism. How -
eve r, although administration of PAF into the  human
nose  causes  kinin generation, there  is no increase  in
sub P re lease . Alternatively, bradykinin can initiate  the
production of the  cytokines IL-1, IL-6 and IL-8 in
v ivo 1 53 and stimulate the  re lease of TNFa / b and IL-1
from macrophage s.15 4 These  cytokine s may contrib-
ute to AHR as  previously mentioned. Inte restingly, the
eosinophilia induced by antigen challenge in the
low er airw ay of the  guinea p ig is  reduced by
bradykinin receptor antagonists 14 3 or an inhibitor of
tissue kallikre in,15 5 thus providing evidence for the
involvement of kinins in the recruitment of eosino-
phils  follow ing ex posure to allergen.
Nas a l a irw ay  hype rre s po n s iven e s s
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FIG. 5. The percentage decrease in the minimal cross-
sectional area of the nasal airway (Am in ) from baseline
10min after challenge with histamine, 200 m g. The nasal
cavity was pretreated with saline (Sal), icatibant (Icat),
200 m g, and/or PAF, 60 m g, 6h prior to the histamine chal-
lenge. Data are means± SEM from 15 subjects. **,+Sig-
nificant increase in the histamine- induced percentage
change in Amin following saline/PAF pretreatment compared
to pretreatment with saline only (**P<0.01, Wilcoxon sign-
rank test) or icatibant/PAF (+P<0.05, Wilcoxon sign-rank
test).
FIG. 6. The effect of PAF on the concentration of kinins in
nasal lavage fluid. The nasal airway was challenged with
either saline or PAF, 60 m g, and the airway was lavaged 2, 4
and 6h after challenge. Data are means± SEM from 13
subjects. *Significant increase (P<0.05) in levels of kinin
following challenge with PAF compared to saline (Wilcoxon
sign-rank test).
The role of inflammatory cells in
hyperresponsiveness
From the evidence pre sented, it might appear that
eosinophils  have a vital role  in the  deve lopment of
AHR. However, the re lationship be tw een eosinophil
activation and AHR remains controversial. Ce rtainly,
eosinophils  are involved in the  late  response , but the
development of AHR may not be  dependent on the
presence of eosinophils. Studie s conducted in animal
mode ls indicate that AHR can occur w ithout a
dete ctable eosinophilia, and vice  versa.1 56 Data
obtained from studie s in the human nose s imilarly
imply that AHR doe s not ne cessarily occur together
w ith eosinophil ac tivation,48 ,49 w hile antigen can
induce an eosinophilia w ithout causing AHR.1 57 There
are  a range of airw ay inf lammatory conditions w hich
feature an eosinophilic infiltration, but no assoc iated
AHR.22 None the less, the close association betw een
eosinophil recruitment, ac tivation and AHR in many
studies35 ,52 ,67 implies, at the very least, that eosino-
phils  may contribute  to the deve lopment of AHR.
Although eosinophils are  the  main ce lls w hich have
been implicated in the  mechanism underlying AHR, it
is like ly that other cells are  involved, including
neutrophils , T-lymphocytes, macrophage s, B-cells and
basophils.7 1 Basophils, w hich may be  involved in the
late alle rgic  re sponse , are capable of gene rating
histamine, bradykinin, MBP, LTC4 , IL-4 and IL-8,
71 ,15 8
w hich may contribute  to AHR. Macrophage s may also
be involved in the development of nasal AHR, possibly
by generating cytokine s and free radicals.1 59
The  involvement of the neutrophil in AHR is  often
overlooked, yet there  is a w ealth of evidence  for an
active role. Not only may they contribute to the
generation of kinins and cause  tissue  damage via the
supe rox ide burst, but they also generate PAF, LTB4
and a variety of cytokine s. It is interesting to note that
ECP has now  been detected in neutrophils.16 0 Neu-
trophils isolated from atopic  subjects have an
incre ased capac ity for myelope rox idase  re le ase, and
this enzyme can generate nitric ox ide-derived ox i-
dants, w hich can induce AHR and inhibit kininase  II,
an enzyme responsible for the  metabolism of
P. J. Tu rn e r & J. C. Fo rem an
142 Mediators of Inflammation ´ Vol 8 ´ 1999
FIG. 7. Putative mechanism for the development of airway hyperresponsiveness.
kinins .1 41 The  hypothesis  that both neutrophils and
eosinophils  ac t together in causing AHR is one w hich
w arrants  furthe r inve stigation.
The  upregulation of ICAM-1 and VCAM-1 by cyto-
kines in allergic  rhinitis has  alre ady been discussed.
ICAM-1 and VCAM-1, present on endothe lial cells,
bind respective ly to integrins LFA-1 ( a Lb 2 integrin)
and VLA-4 ( a 4 b 1 integrin) on leukocyte s, allow ing
leukocyte s to adhere  to the  endothe lium prior to
migration. The inte raction be tw een VCAM-1 and VLA-
4 appears  to be  particularly important in eosinophil
migration, as neutrophils do not have the  VLA-4
receptor on their surface.1 61 Interfe ring w ith the
VCAM-1/VLA-4 pathw ay may, there fore , prevent eosi-
nophil-dependent hyperre sponsivene ss. Monoclonal
antibodie s (mAbs) to the  integrin sub-unit a 4 have
been developed w hich abolish antigen-induced
hyperresponsiveness in the  low er airw ays of a num-
ber of animal mode ls  of airw ay alle rgy.1 62 –1 64 Inte r-
estingly, this  e ffec t w as  not alw ays associated w ith an
decre ase in the  airw ay eosinophilia,1 63 ,1 65 possibly
because  other mechanisms ex ist (e .g. via ICAM-1)
w hereby eosinophil migration may occur. Further
development of these mAbs may provide a useful
therapeutic intervention for airw ay alle rgy in man.
Summary
It w ould appear that a number of mediators are
capable  of inducing AHR in the human nasal airw ay,
perhaps acting via different mechanisms, w hich
w ould help ex plain the conflic ting evidence regard-
ing a role  for eosinophils  or airw ay epithe lial damage
in this proce ss. How eve r, the  fac t that inhibitors of
leukotriene s, PAF, kinins and tachykinins can all
inhibit antigen-induced AHR implie s that there  may be
a central common pathw ay in the  pathogenesis  of
AHR. Since neurogenic inflammation can potentially
be modulated by all of the se mediators, neuropep-
tides may be  involved in the final stage of AHR
induction, perhaps as show n in Fig. 7. Antagonists of
these  mediators appear to inhibit the development of
hyperresponsiveness in animals, and the deve lopment
of similar antagonists for use  in man may provide new
pharmacologic al treatments for allergic  rhinitis , and
perhaps for other alle rgic  airw ay dise ases as we ll.
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